Anti-angiogenic agents are believed to hold great promise in the fight against cancer. With more than 20 of such agents in different stages of clinical development, angiogenesis inhibitors are considered one of the most exciting areas of cancer research today.
Recent setbacks in the clinical development of several matrix metalloproteinase inhibiting compounds and fast progress in the area of signal transduction suggest that targeting tyrosin kinase and Vegf signaling pathways seems to be the most promising technological venue for bringing a product to the market soon.
Pharmacia, Pfizer, Bristol-Myers Squibb, AstraZeneca, Novartis, American Home Products and Genentech have all recognized this viable research venue and have initiated research activities in the field either through in-licensing or through acquisitions. With so much research directed and money thrown at the field of angiogenesis inhibition we believe that a viable market will be created by 2006 with the first product entering the market as early as 2004.
Angiogenesis Inhibitors 2001 describes the different technological strategies employed to develop anti-angiogenic agents as cancer therapeutics and assesses the potential of drugs currently in clinical trials. Angiogenesis Inhibitors 2001 edition features updated analysis of biopharmaceutical leaders in angiogenesis medicine, their technologies and their product pipelines. It also envisions different market development scenarios and provide forecasts for the year 2006.
